TWIST BIOSCIENCE CORP
TWSTNASDAQTrading Snapshot
- Day Range
- $121.28 β $124.56
- 52-Week Range
- $23.30 β $125.66
- Volume
- $6.77B
- Avg Volume
- $5.45B
- Shares Outstanding
- 62.3M
- Next Earnings
- Oct 16, 2026
Fundamentals Snapshot
- Annual Revenue
- $377M
- Last Q Revenue
- $118M
- P/E Ratio
- β
- P/S Ratio
- 18.1x
- EPS (TTM)
- $-2.22
- Dividend Yield
- β
Why Investors Own TWST
- βHigh-growth profile β revenue up +12.4% YoY with expanding US Equity exposure.
- βHealthy economics β 75% gross margin and 11% free-cash-flow margin.
- βNew products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About TWIST BIOSCIENCE CORP
Twist Bioscience Corporation operates as a leading synthetic biology firm, specializing in the production and sale of products developed from synthesized DNA. The company utilizes a unique DNA synthesis platform that facilitates the creation of artificial DNA by "writing" it directly onto silicon chips. Its extensive product catalog encompasses custom synthetic genes, specialized tools designed for sample preparation, comprehensive antibody libraries essential for pharmaceutical research and development, and advanced applications leveraging DNA for digital data storage. Twist Bioscience has established strategic collaborations with several organizations, including Victorian Clinical Genetic Services, Vivlion GmbH, Kyowa Kirin Pharmaceutical Research, Inc., deepCDR Biologics AG, and Centogene N.V., with the shared goal of innovating advanced sequencing technologies. Furthermore, the company engages in a research alliance with Boehringer Ingelheim International GmbH, where it applies its exclusive antibody libraries to identify and develop therapeutic antibodies against a multitude of targets. The corporation was founded in 2013 and is headquartered in South San Francisco, California.
Otter Score Breakdown
βAnalyst Ratings
βLatest News & Updates
Recursion Pharmaceuticals: I'm Still Bearish Despite Recent Genentech News
Recursion Pharmaceuticals, Inc. stock is a Hold: slow revenue, competition, cash burn & dilution risk despite Roche/Sanofi deals. Click for this RXRX update.
Twist Bioscience Corporation 2026 Q3 - Results - Earnings Call Presentation
2026-08-07. The following slide deck was published by Twist Bioscience Corporation in conjunction with their 2026 Q3 earnings call.
Artisan Global Discovery Fund Q2 2026 Portfolio Activity
During the quarter, we initiated new positions in Entegris, Cellebrite and C.H. Robinson.
Piper Sandler Maintains Overweight on Twist Bioscience, Raises Price Target to $115
Piper Sandler analyst David Westenberg maintains Twist Bioscience (NASDAQ:TWST) with a Overweight and raises the price target from $85 to $115.
Twist Biosciences: Accelerating Growth, Diminishing Margin Of Safety
Twist Bioscience (TWST) is surging in 2026 on AI-enabled drug discovery growth and improving margins, but valuation looks demandingΓ’ΒΒread the outlook.
The BioRevolution Has Accelerated
WisdomTree BioRevolution Fund delivered a dramatic acceleration in performance over S&P 500 Index, thereby drawing attention to this particular investment theme. Read more here.